<DOC>
	<DOCNO>NCT02638428</DOCNO>
	<brief_summary>The purpose study evaluate efficacy feasibility combination chemotherapy target agent accord result target deep sequencing pediatric patient relapsed/refractory solid tumor AML .</brief_summary>
	<brief_title>Genomics-Based Target Therapy Children With Relapsed Refractory Malignancy</brief_title>
	<detailed_description>Outcome pediatric cancer improve substantially past decade , prognosis relapsed/refractory pediatric cancer still remain poor . Advances genomic technology improve ability detect diverse somatic germline genomic aberration cancer patient , incorporate clinical management cancer . Samsung Genomic Institute develop target next-generation sequencing ( NGS ) platform , CancerSCAN™ , detect clinically significant genomic aberration tumor . In study , tumor sample refractory/relapsed pediatric cancer patient test CancerSCAN™ patient receive combination chemotherapy match single-targeted agent multi-targeted receptor tyrosine kinase inhibitor accord result CancerSCAN™ . I. Relapsed/refractory solid tumor - Perform CancerSCAN™ enrollment - Conventional chemotherapy ( ifosfamide , carboplatin , etoposide ) match single-targeted agent ( axitinib , crizotinib , dasatinib , erlotinib , everolimus , imatinib , pazopanib , ruxolitinib , sorafenib , vandetanib , vemurafenib , trastuzumab ) multi-targeted receptor tyrosine kinase inhibitor ( pazopanib sorafenib ) accord result CancerSCAN™ II . Relapsed/refractory AML - Perform CancerSCAN™ enrollment - Conventional chemotherapy ( fludarabine , cytarabine ) match single-targeted agent ( axitinib , crizotinib , dasatinib , erlotinib , everolimus , imatinib , pazopanib , ruxolitinib , sorafenib , vandetanib , vemurafenib , trastuzumab ) multi-targeted receptor tyrosine kinase inhibitor ( pazopanib sorafenib ) accord result CancerSCAN™</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Under 18 year age initial diagnosis Patients refractory/relapsed solid tumor AML ( Solid tumor : Stable progressive disease 1stline treatment relapse ; AML : Persistence 2 cycle induction chemotherapy relapse ) Patient tumor sample adequate target deep sequencing Patients salvage chemotherapy previously Patients organ dysfunction follow ( creatinine elevation ≥ 3 x upper limit normal ( ULN ) , ejection fraction &lt; 40 % , significant arrhythmia conduction disturbance ) Patients eligible scheduled treatment due significant impaired organ function Patients whose tumor sample sufficient targeted deep sequencing Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>